Phase 3 N=446 A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy
Bronchoscopy
Primary: Number of Participants With a Successful Procedure — 250; 3; 24 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=478 Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Prostate Cancer
Primary: Time to Progression — 683.0; 549.0 days — p=0.76
N/A N=120 Optimal VAsopressor titraTION Pilot Randomized Controlled Trial
Hypotension · Shock
Primary: MAP While on Vasopressors — 79; 70 mmHg
Phase 2 N=48 Inhaled Nitrite in Subjects With Pulmonary Hypertension
Pulmonary Hypertension · Heart Failure, Diastolic
Primary: Change in Pulmonary Vascular Resistance (PVR) — 0.77; 0.40; -0.39 Woods units — p=0.002
N/A N=70 Needle-Guided vs Free-Hand Technique in Performing Brachial Plexus Blockade
Needle Guidance; Nerve Blocks
Primary: Needle Time; — 106; 197 seconds
Phase 2 N=42 Enzalutamide in Patients With High-risk Prostate Cancer
Adenocarcinoma of the Prostate
Primary: To Evaluate the Clinical Efficacy of Enzalutamide — 31 months
Phase 2 N=256 A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Diabetic Nephropathies
Primary: Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12 — 195.130; 182.378; 9.072; -6.539 mg/mmol — p=0.9889
Phase 3 N=2,243 An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
Ulcerative Colitis · Crohn's Disease
Primary: Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 93; 96; 31; 41 percentage of participants
Phase 2 N=52 Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
Primary Sclerosing Cholangitis
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase — 81.8; 70.0; 100.0 percentage of participants
Phase 1 N=53 Study of MLN8237 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Part A: Dose-normalized Cmax (Maximum Observed Concentration) for Estimation of Relative Bioavailability for Alisertib Oral Solution (OS) Versus Powder in Capsule…
N/A N=245 Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
Tobacco Dependence
Primary: Number of Participants Who Dropped Out of Study as a Measure of Adherence — 52; 19 Participants — p=<0.0001
N/A N=169 An Educational Intervention for Type 2 Diabetes Patients
Diabetes Mellitus
Primary: Patients' Perceived Self-efficacy to Communicate — 22.11; 22.14; 23.44; 22.63 units on a scale
Phase 3 N=282 BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
Colorectal Carcinoma
Primary: Overall Survival — 4.44; 4.76 Months — p=0.337
N/A N=43 Micra Accelerometer Sensor Study 2
Bradyarrhythmia
Primary: Waveform and Components of Accelerometer Signal — 0.15601; 0.19222; 0.14398 g (unit (g) represent acceleration)
Phase 4 N=276 Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
Chronic Liver Disease
Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s